AKEBIA THERAPEUTICS, INC. Deferred Tax Assets, Operating Loss Carryforwards
AKEBIA THERAPEUTICS, INC. (AKBA) had Deferred Tax Assets, Operating Loss Carryforwards of $289.71 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $289.71M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $291.72M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $288.94M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $288.84M; Deferred Tax Assets, Operating Loss Carryforwards as first filed $288.15M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $289.71M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $291.72M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $288.94M 10-K · filed 2025-03-13 | |
| 2022-12-31 | $288.84M 10-K · filed 2024-03-14 | $288.15M 10-K · filed 2023-03-10 |
| 2021-12-31 | $287.19M 10-K/A · filed 2023-08-28 | $286.91M 10-K · filed 2022-03-01 |
| 2020-12-31 | $262.53M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $242.17M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $189.84M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $42.34M 10-K · filed 2019-03-26 | |
| 2016-12-31 | $84.37M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $51.36M 10-K · filed 2017-03-06 | |
| 2014-12-31 | $30.56M 10-K · filed 2016-03-14 | $30.56M 10-K · filed 2015-03-04 |
| 2013-12-31 | $17.92M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |